Halozyme Therapeutics (NASDAQ:HALO) Upgraded to “B” by TheStreet

TheStreet upgraded shares of Halozyme Therapeutics (NASDAQ:HALO) from a c+ rating to a b rating in a research note released on Monday, TheStreetRatingsTable reports.

Several other analysts have also recently weighed in on HALO. Evercore ISI began coverage on Halozyme Therapeutics in a research report on Monday, June 14th. They set an outperform rating on the stock. Zacks Investment Research cut Halozyme Therapeutics from a buy rating to a hold rating and set a $45.00 price objective on the stock. in a research report on Friday, July 16th. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of Buy and an average price target of $51.67.

Shares of NASDAQ:HALO opened at $41.17 on Monday. Halozyme Therapeutics has a 1 year low of $25.17 and a 1 year high of $56.40. The company has a market cap of $5.86 billion, a PE ratio of 26.39 and a beta of 1.43. The company has a debt-to-equity ratio of 6.56, a current ratio of 8.75 and a quick ratio of 8.24. The stock’s 50-day moving average is $41.40 and its 200 day moving average is $43.10.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Monday, August 9th. The biopharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.43 by $0.19. Halozyme Therapeutics had a return on equity of 230.77% and a net margin of 55.45%. The company had revenue of $136.50 million for the quarter, compared to the consensus estimate of $104.08 million. During the same quarter in the previous year, the business earned $0.19 EPS. Halozyme Therapeutics’s revenue was up 147.3% compared to the same quarter last year. Analysts expect that Halozyme Therapeutics will post 1.82 EPS for the current fiscal year.

In other news, Director Jean-Pierre Bizzari sold 35,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 25th. The stock was sold at an average price of $41.01, for a total value of $1,435,350.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Helen Torley sold 50,000 shares of the business’s stock in a transaction that occurred on Tuesday, July 6th. The stock was sold at an average price of $45.97, for a total transaction of $2,298,500.00. Following the completion of the transaction, the chief executive officer now owns 587,160 shares of the company’s stock, valued at $26,991,745.20. The disclosure for this sale can be found here. Over the last three months, insiders sold 225,315 shares of company stock worth $9,750,746. Insiders own 2.60% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Oberweis Asset Management Inc. raised its holdings in Halozyme Therapeutics by 0.4% in the 2nd quarter. Oberweis Asset Management Inc. now owns 69,200 shares of the biopharmaceutical company’s stock worth $3,142,000 after acquiring an additional 300 shares during the last quarter. Bank of Montreal Can raised its stake in Halozyme Therapeutics by 0.3% during the 2nd quarter. Bank of Montreal Can now owns 121,193 shares of the biopharmaceutical company’s stock valued at $5,553,000 after buying an additional 303 shares during the last quarter. Assetmark Inc. raised its stake in Halozyme Therapeutics by 32.8% during the 1st quarter. Assetmark Inc. now owns 1,235 shares of the biopharmaceutical company’s stock valued at $51,000 after buying an additional 305 shares during the last quarter. Profund Advisors LLC raised its stake in Halozyme Therapeutics by 2.8% during the 2nd quarter. Profund Advisors LLC now owns 11,223 shares of the biopharmaceutical company’s stock valued at $511,000 after buying an additional 307 shares during the last quarter. Finally, Securian Asset Management Inc raised its stake in Halozyme Therapeutics by 3.0% during the 2nd quarter. Securian Asset Management Inc now owns 12,300 shares of the biopharmaceutical company’s stock valued at $559,000 after buying an additional 355 shares during the last quarter. Institutional investors own 89.92% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

Recommended Story: Cost of Capital Explained

Analyst Recommendations for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.